Brigatinib-induced tuberculosis reactivation: A case report

KEŞ V., SÜTCÜOĞLU O., GÜRLER F., YAZICI O., ÖZET A.

Current Problems in Cancer, cilt.45, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.currproblcancer.2021.100738
  • Dergi Adı: Current Problems in Cancer
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: Immunodeficiency, Lymphopenia, Tyrosine kinase inhibitor, Lung cancer, PULMONARY TUBERCULOSIS
  • Gazi Üniversitesi Adresli: Evet

Özet

© 2021 Elsevier Inc.Brigatinib is a novel potent tyrosine kinase inhibitor as third-generation therapy for anaplastic lymphoma kinase (ALK) rearrangement positive non-small cell lung cancer (NSCLC). Clinical trials show that brigatinib is potent choice of treatment for the first line and further lines of treatment of ALK rearranged NSCLC with highly potent anti-tumor effect on brain metastasis. The adverse effects of brigatinib are tolerable and managable. However, there is limited data about effects on immune system. The most possible serious adverse effect of brigatinib on immune system might be brigatinib associated grade 3-4 lymphopenia. Here we report a brigatinib-induced tuberculosis reactivation patient who is using third-line brigatinib for metastatic NSCLC and have partial response.